The paper highlights the need to understand and address the progression of cardiorenal disease in patients already receiving chronic RAAS suppression.
Cardiorenal progression may continue on chronic RAAS suppression; leaves open targeted adjunctive strategies for future trials.
Drugs suppressing the renin-angiotensin-aldosterone system (RAAS) are now widely used to treat patients all along the cardiorenal continuum. It supposes that many patients, in particular those with arterial hypertension are treated with converting-enzyme inhibitors and angiotensin receptor blockers for years during which the development and prograssion of cardiorenal disease can be observed. The meaning of this progression in the presence of RAAS suppression requires to be clarified and to be treated in order to diminish the velocity of progression of cardiorenal disease.
No takes yet. Share an insight, caveat, or question.
Sarafidis et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: